Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and vibrators.
Popular Articles

Obama Has Larger Pool Of Female Judges To Select From For Supreme Court Nominee
In selecting a Supreme Court nominee, President Obama will have a more diverse pool of judges to choose from than his predecessors did, largely because the number of women on the federal bench has increased dramatically over the past two decades, the AP/Kansas City Star reports. Just two of the 110 justices that have served on the Supreme Court are women: former Justice Sandra Day O"Connor and current Justice Ruth Bader Ginsburg. Most of the candidates Obama is considering are women.According to the AP/Star, there are 212 full-time female judges serving in the federal courts, meaning that women make up more than one quarter of the federal judiciary. In contrast, there were about 40 female federal judges during the Reagan administration. In addition, women make up at least 40% of the judges on 22 of the 53 state supreme courts, another likely for nominees. The AP/Star reports that the increase in the number of female judges reflects the rise in the number of practicing female lawyers; women currently account for about one-third of lawyers and nearly half of all law school graduates. Marcia Greenberger, co-president of the National Women"s Law Center, said, "I wouldn"t say the doors have swung open as fully as we would like." She added, "Nonetheless, there are superb women in the judiciary, academia and private practice."The AP/Star also reports that Obama might seek to increase racial diversity on the Supreme Court, as only two of the 110 justices have been black men: current Justice Clarence Thomas and former Justice Thurgood Marshall. There has never been a Hispanic, Asian-American or American Indian justice (Sherman, AP/Kansas City Star, 5/20).
buy viagra
MabThera To Reduce The Progression Of Joint Damage When Used As A First-line Biologic Treatment In RA
New data show for the first time that a course of 2 infusions of MabThera 1000mg (rituximab, known as Rituxan within the United States) given every 24 weeks as the patient"s first biologic can significantly slow down joint damage following 1 year of treatment, with virtually no progression of joint damage seen from six months1.
News of the day
The Possible Roles Of Solar Ultraviolet-B Radiation And Vitamin D In Reducing Case-Fatality Rates From The 1918-1919 Influenza Pandemic In EU
An estimated 675,000 Americans died from the A/H1N1 pandemic influenza in the United States in 1918-1919. Many of these deaths were from ensueing bacterial pneumonia rather than directly from the viral infection. The United States Public Health Service conducted surveys in twelve cities and rural areas of the country in late 1918 to early 1919 to determine the case-fatality rate in each city or area. Case-fatality rates varied from 0.78 deaths/100 cases in San Antonio, Texas to 3.14 deaths/100 cases in New London, Connecticut. The strong variation with location suggested that solar ultraviolet-B (UVB) irradiance, through production of vitamin D, reduced the risk of death following infection by this pandemic influenza.
Oncology

New Protein Center Opens At The University of Copenhagen

On the 4th June, the Faculty of Health Sciences at the University of Copenhagen will open the doors of its new research center, The Novo Nordisk Foundation Center for Protein Research. The Center is the result of a historic donation from the Novo Nordisk Foundation, which in 2007 gave the University 80 million euros for its establishment. The protein center, headed by director Michael Sundstrç¶m, will be housed in three recently renovated floors of the Panum Institute in Copenhagen. With its over 150 international researchers, ultramodern laboratories and advanced instrumentation, the center will be a beacon in the field of protein research. "With the establishment of the research center (CPR), Danish protein research will acquire working facilities that make frontline research possible," explains Dean Ulla Wewer. World-class Research The unique construction of the center, which encourages synergistic collaboration between several disciplines, including protein characterisation, proteomics, systems biology and disease biology will provide the optimal environment for the scientists and has already attracted leading international researchers to the University of Copenhagen. "The facilities are the best currently available, and as we have all the basic financing in place, our researchers are free to concentrate on their work and look forward to groundbreaking results, explains Ulla Wewer." Proteins Provide Answers By combining the study of proteins in diseased and healthy cells with the ability of computer technology to process enormous quantities of data, the center"s prospect is to uncover the causes of a range of deadly diseases and thereby contribute to the development of new and effective treatments. "It requires profound insight into the biology of disease to develop new and targeted methods of medical treatment. Our aim is to record and understand the changes taking place in proteins that can lead to disease", explains director Michael Sundstrç¶m and stresses that the Protein Center opens up new opportunities for investigating the complicated progression from protein to disease. The research will first and foremost benefit those whom it ultimately serves: The people who are afflicted with serious disease and for whom effective treatment is not currently available. At the same time, health science research conducted at universities and hospitals will be able to have access to a valuable re and companies in the region will benefit from the knowledge and techniques that the center produces. Students can be introduced to the practises, methods and equipment that will prepare them for work at the highest international level. University Copenhagen


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009